Does an Adequate Dose of Cisplatin Need to Achieve Better Disease Control and Overall Survival in Locally Advanced Nasopharyngeal Carcinoma?
Xiaomin Ou(Fudan University Shanghai Cancer Center), Chaosu Hu(Ministry of Agriculture and Rural Affairs), Wei Jiang(Shanghai Medical College of Fudan University), Xujiao Zhou(Fudan University), Ye Yang(Shanghai Medical College of Fudan University), Xiqian Xing(Yunnan University), Qianling Shi(Shanghai Medical College of Fudan University)
International Journal of Radiation Oncology*Biology*Physics
October 1, 2016
Cited by 0
Related Papers
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
|Journal of Clinical Oncology|2021|393
International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma
|Radiotherapy and Oncology|2017|374
Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice
|Nature Biotechnology|2021|186
International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma
|International Journal of Radiation Oncology*Biology*Physics|2019|183